Omadacycline Tosylate
Brand name: Nuzyra
Rank #493 of 500 drugs by total cost
$14.1M
Total Cost
1,395
Total Claims
$14.1M
Total Cost
72
Prescribers
$10K
Cost per Claim
331
Beneficiaries
1,414
30-Day Fills
$197K
Avg Cost/Provider
19
Avg Claims/Provider
About Omadacycline Tosylate
Omadacycline Tosylate (sold as Nuzyra) was prescribed 1,395 times by 72 Medicare Part D providers in 2023, costing the program $14.1M. At $10K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 490 | Bexarotene (Bexarotene) | $14.2M | 1,613 |
| 491 | Ozanimod Hydrochloride (Zeposia) | $14.2M | 1,535 |
| 492 | Enoxaparin Sodium (Enoxaparin Sodium) | $14.2M | 93,202 |
| 493 | Omadacycline Tosylate (Nuzyra) | $14.1M | 1,395 |
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology